Zobrazeno 1 - 10
of 103
pro vyhledávání: '"R. Gentilella"'
Autor:
Francesco Giorgino, R. Gentilella, Marco Orsini Federici, Kristina S. Boye, Bruno Guerci, Hélène Sapin, U. Aigner, Luis-Emilio Garcia-Perez, Heike Jung, E. Heitmann, Kirsi Norrbacka, Myriam Rosilio
Publikováno v:
Diabetes Therapy
Introduction The TROPHIES observational study enrolled patients with type 2 diabetes mellitus (T2DM) initiating their first injectable treatment with the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) dulaglutide or liraglutide. This manuscrip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b3086660553c8107e7ebba45cb6e4b
https://doi.org/10.1007/s13300-021-01076-0
https://doi.org/10.1007/s13300-021-01076-0
Autor:
Irene Romera, R. Gentilella, Raffaella Buzzetti, Claudia Nicolay, Giorgio Sesti, Luis Alberto Vázquez
Publikováno v:
Diabetes Ther . 2019 Jun;10(3):1113-1125
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Introduction: This exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b1bc7aae19e4e06c16a7d6f42fd8db0
https://doi.org/10.1007/s13300-019-0625-3
https://doi.org/10.1007/s13300-019-0625-3
Autor:
Bruno Guerci, H Sapin, R. Gentilella, Heike Jung, Francesco Giorgino, Marco Orsini Federici, U. Aigner, KS Boye, Luis-Emilio Garcia-Perez, Kirsi Norrbacka, E. Heitmann, Myriam Rosilio
Publikováno v:
Präzisionsmedizin – Eine Reise in die Zukunft der Diabetologie www.diabeteskongress.de.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75674ae10f4a40123b5c32d63cc30e69
https://doi.org/10.1055/s-0041-1727304
https://doi.org/10.1055/s-0041-1727304
Publikováno v:
Diabetes/Metabolism Research and Reviews
Despite the importance of individualised strategies for patients with type 2 diabetes mellitus (T2DM) and the availability of alternative treatments, including glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), sulphonylureas are still wide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a1a91058c3442b0219a747646cbca91
https://pubmed.ncbi.nlm.nih.gov/33900667
https://pubmed.ncbi.nlm.nih.gov/33900667
Autor:
Irene Romera, Jesús Reviriego, R. Gentilella, Esteban Jódar, Luis Alberto Vázquez, Ignacio Conget, Jeremie Lebrec
Aims. To determine the early benefit:risk balance of dulaglutide versus insulin glargine in patients with type 2 diabetes mellitus (T2DM). Methods. This post hoc analysis used data from a randomized, open-label study (AWARD-2; modified intention-to-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca68c32b19006002d2bab2226b16d6e3
https://hdl.handle.net/11268/11220
https://hdl.handle.net/11268/11220
Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus
Publikováno v:
Diabetes & Metabolism. 43:501-511
Many people with type 2 diabetes mellitus (T2DM) fail to achieve glycaemic control promptly after diagnosis and do not receive timely treatment intensification. This may be in part due to 'clinical inertia', defined as the failure of healthcare provi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501e6cf30ed2d36af79d8fb372537632
https://doi.org/10.1016/j.diabet.2017.06.003
https://doi.org/10.1016/j.diabet.2017.06.003
Publikováno v:
Diabetologie und Stoffwechsel. 12:S1-S84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdcc33c2ca3f14b0093f7ac7a146cc63
https://doi.org/10.1055/s-0037-1601745
https://doi.org/10.1055/s-0037-1601745
Autor:
R. Gentilella, Paolo Pozzilli, Victoria Reed, Luis Alberto Vázquez, Hélène Sapin, Giorgio Sesti, Irene Romera
Publikováno v:
Diabetes, obesitymetabolismREFERENCES. 21(12)
AIM To assess the relationship between baseline body mass index (BMI) and glycaemic control in dulaglutide-treated patients, a post hoc analysis was conducted on HbA1c and baseline BMI data from eight AWARD studies, with a total of 5770 patients. MAT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab9152b81e9c807b279cdeeb3f21e9ba
https://pubmed.ncbi.nlm.nih.gov/31392822
https://pubmed.ncbi.nlm.nih.gov/31392822
Autor:
Jessica B Jordan, Marco Orsini Federici, R. Gentilella, Katie D. Stewart, Kristina S. Boye, Louis S. Matza, Giovanni Biricolti, Silvia Del Santo, Kirsi Norrbacka, Serena Losi, Magaly Perez-Nieves
Aims: Several glucagon like peptide-1 (GLP-1) receptor agonists are available as weekly injections for treatment of type 2 diabetes. These medications vary in their injection devices, and these differences could impact quality-of-life and patient pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::394e504b942285139bbcef13c6995681